A Study to Evaluate the Efficacy and Safety of JS002 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH).

NCT05325203 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

135

Enrollment

OTHER

Sponsor class

Conditions

Heterozygous Familial Hypercholesterolemia

Interventions

BIOLOGICAL: Ongericimab
DRUG: Placebo

Sponsor

Shanghai Junshi Bioscience Co., Ltd.